Acute Lymphoblastic Leukemia (ALL)

Study Identifies Factors Associated With Infection-related Complications in ALL

Study Identifies Factors Associated With Infection-related Complications in ALL

By

Data on neutropenia and infection-related complications in patients with ALL are lacking; therefore, this study focused on identifying the characteristics and risk factors of infection-related complications in children with newly diagnosed ALL.

Internalizing, Externalizing Behavioral Problems a Significant Postdiagnosis Concern in Children With Cancer

Internalizing, Externalizing Behavioral Problems a Significant Postdiagnosis Concern in Children With Cancer

By

Children with cancer are at risk for developing behavioral problems after diagnosis.

Hyper-CVAD + Ponatinib May Be Superior to Hyper-CVAD + Dasatinib in Ph+ ALL

By

Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD) plus ponatinib appears to be superior to hyper-CVAD plus dasatinib for the frontline treatment of patients with Philadelphia chromosome-positive ALL.

Post-transplant Maintenance TKIs Beneficial for Patients With High-risk Ph+ Leukemia

Post-transplant Maintenance TKIs Beneficial for Patients With High-risk Ph+ Leukemia

By

A study examined the impact of post-transplant maintenance TKIs on patients with Ph+ acute lymphoblastic leukemia and chronic myeloid leukemia.

Intensive Protocol Improves Survival for Adults with Acute Lymphoblastic Leukemia

Intensive Protocol Improves Survival for Adults with Acute Lymphoblastic Leukemia

By

Event-free survival for adult patients with ALL has improved from 40% to 73% with the implementation of the NOPHO ALL 2008 protocol in July 2008.

Blinatumomab Improves Overall Survival in Acute Lymphoblastic Leukemia

By

Overall survival for patients with acute lymphoblastic leukemia (ALL) was nearly doubled to 7.8 months from 4.0 months by treating patients with blinatumomab compared with standard of care.

Higher Concentrations of Methotrexate for Pediatric Leukemia Affect Long-Term Cognitive Processes

Higher Concentrations of Methotrexate for Pediatric Leukemia Affect Long-Term Cognitive Processes

By

Pediatric patients with ALL treated with methotrexate can experience challenges with mental flexibility and organization compared with expectations from the general population.

Response to T-cell Immunotherapy Promising for Patients With Advanced B-cell Acute Lymphocytic Leukemia

Response to T-cell Immunotherapy Promising for Patients With Advanced B-cell Acute Lymphocytic Leukemia

By

Remission was achieved for 27 of 29 patients with advanced B cell acute lymphocytic leukemia (ALL) in an early phase trial of CAR T cells.

Challenges faced in the treatment of acute lymphoblastic leukemia in adolescents and young adults

Challenges faced in the treatment of acute lymphoblastic leukemia in adolescents and young adults

[Clinical Oncology in Adolescents and Young Adults] This research reviews the outcomes with chemotherapy alone and with hematopoietic stem cell transplantation in acute lymphoblastic leukemia, and examines the challenges faced in determining the best therapy for the adolescents and young adult patient population.

Anxiety and Depressive Symptoms Are Increased in Pediatric Survivors of Acute Lymphoblastic Leukemia

By

Emotional distress during and after undergoing chemotherapy for ALL affects a significant percentage of children with the disease.

New Possible Treatment Addresses Specific Type of Leukemia

By

A subtype-specific weakness of T-cell acute lymphoblastic leukemia (T-ALL) could enable improved treatment, according to results from a a recent study using a mouse model.

Study Findings Show Possible Association Between PreLabor Cesarean Delivery and Risk for ALL in Young Children

By

The finding that prelabor cesarean delivery may have a correlation with acute lymphoblastic leukemia (ALL) may offer new targets for research into preventing cancer.

Early Lineage T Cells Are Better for Immunotherapy in Pediatric Patients With ALL and Lymphoma

Early Lineage T Cells Are Better for Immunotherapy in Pediatric Patients With ALL and Lymphoma

By

Outcomes from a novel personalized cell therapy may be improved if specific subtypes of T cells are selected to attack diseases such as acute lymphoblastic leukemia and lymphoma.

Long-term Attention and Learning Deficits Persist After Chemotherapy for Pediatric Leukemia

By

Pediatric survivors of ALL treated only with chemotherapy remain at an increased risk for attention problems 2 years after treatment cessation.

Chromosomal Rearrangements Initiate High-risk Leukemia

By

Abnormal breakage and chromosomal rearrangement in white blood cells result in a particularly aggressive Philadelphia chromosome-like ALL, according to a new study.

Chemotherapy-related Bone Loss in Children With ALL Occurs Earlier Than Previously Assumed

Chemotherapy-related Bone Loss in Children With ALL Occurs Earlier Than Previously Assumed

By

Significant bone loss in children receiving chemotherapy for acute lymphoblastic leukemia (ALL) occurs during the first month of treatment.

Treatment-related Anxiety for Pediatric Patients with Acute Lymphoblastic Leukemia Examined

Treatment-related Anxiety for Pediatric Patients with Acute Lymphoblastic Leukemia Examined

By

A new study examined levels of procedure-related anxiety in children with standard-risk acute lymphoblastic leukemia (ALL).

Association Is Found Between Bone Complications in Young Pediatric Patients With Leukemia and Gene Variations

By

Variations in genes involved in normal bone development are associated with an 8- to 15-fold increased risk for osteonecrosis in young patients with acute lymphoblastic leukemia (ALL).

Antibiotic Prophylaxis During Induction Phase Reduces Infections in Pediatric ALL

Antibiotic Prophylaxis During Induction Phase Reduces Infections in Pediatric ALL

By

Continuous antibiotic treatment can reduce infections in young patients with acute lymphoblastic leukemia (ALL).

Fractures Higher in Non-Hispanic Patients Treated for Newly Diagnosed Pediatric ALL

Fractures Higher in Non-Hispanic Patients Treated for Newly Diagnosed Pediatric ALL

By

Non-Hispanic children undergoing treatment for newly diagnosed acute lymphoblastic leukemia reported higher rates of fractures and opportunistic infections, according to new study data.

Addition of Rituximab Significantly Improved Treatment of Patients With B-cell Non-Hodgkin Lymphoma

Addition of Rituximab Significantly Improved Treatment of Patients With B-cell Non-Hodgkin Lymphoma

By

A new randomized study has evaluated the addition of rituximab to the pediatric-inspired GRAALL protocol for adults with acute lymphoblastic leukemia.

High-Dose Methotrexate Confirmed for Adult Ph- ALL Use

High-Dose Methotrexate Confirmed for Adult Ph- ALL Use

By

Treatment with high-dose methotrexate was linked to significantly higher rates of disease-free survival in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia (ALL), according to results from a recent phase 3 trial.

6MP Self-Reporting in Acute Lymphoblastic Leukemia Deemed 'Unreliable'

6MP Self-Reporting in Acute Lymphoblastic Leukemia Deemed 'Unreliable'

By

Subjective over-reporting of 6-mercaptopurine (6MP) intake during maintenance therapy for childhood acute lymphoblastic leukemia is common, according to a new cohort study.

Inotuzumab Ozogamicin + Low-Intensity Chemo Effective in Older Patients with ALL

Inotuzumab Ozogamicin + Low-Intensity Chemo Effective in Older Patients with ALL

By

Inotuzumab ozogamicin combined with low-intensity mini-hyper-CVD chemotherapy has demonstrated encouraging results in older patients with acute lymphoblastic leukemia, according to data from an ongoing study.

Inherited Gene Variation Linked to an Increased Risk of Pediatric Acute Lymphoblastic Leukemia (ALL)

Inherited Gene Variation Linked to an Increased Risk of Pediatric Acute Lymphoblastic Leukemia (ALL)

By

Researchers studying two generations of a family affected by pediatric ALL identified an inherited variation in the ETV6 gene that is associated with an increased risk of developing the disease.

Unraveling of molecular changes in acute lymphoblastic leukemia (ALL) opens new treatment options

By

An international team has decoded the molecular characteristics of acute lymphoblastic leukemia (ALL), a cancer with some incurable subtypes.

Preclinical data shows promise for pediatric acute lymphoblastic leukemia

Preclinical data shows promise for pediatric acute lymphoblastic leukemia

By

A recently developed drug holds great promise for some children with acute lymphoblastic leukemia (ALL).

Study pinpoints genetic cause of increased leukemia risk

Study pinpoints genetic cause of increased leukemia risk

By

A mutation of the gene ETV6 has been pinpointed as the heritable, genetic cause of acute lymphoblastic leukemia (ALL), according to a study.

Chromosomal rearrangement is key to progress against aggressive infant leukemia

By

Current research indicates that a rare but aggressive subtype of pediatric acute lymphoblastic leukemia (ALL) has surprisingly few mutations beyond the chromosomal rearrangement that affects the MLL gene.

Childhood leukemia study reveals disease subtypes and new treatment options

Childhood leukemia study reveals disease subtypes and new treatment options

By

Acute lymphoblastic leukemia (ALL) has been found to have two distinct subtypes, and evidence indicates that roughly 13% of ALL cases may be successfully treated with targeted drugs used in the treatment of lymphomas in adults.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs